Dossier
breakthrough device program
Coverage of breakthrough device program in the Nexus archive.
- STAT+: What an abandoned heart failure trial says about ‘breakthrough’ devices that don’t reach patients
LivaNova's VITARIA vagus nerve stimulator for heart failure, designated a FDA breakthrough device, failed to meet trial success criteria after enrolling 500 patients. The FDA's breakthrough device program, aimed at accelerating innovative treatments, did not ensure the device's market success.